Back to top
more

Hims & Hers Health (HIMS)

(Delayed Data from NYSE)

$12.27 USD

12.27
2,292,642

-0.07 (-0.57%)

Updated Apr 25, 2024 04:00 PM ET

After-Market: $12.26 -0.01 (-0.08%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

Hims & Hers Health, Inc. (HIMS) Stock Sinks As Market Gains: What You Should Know

Hims & Hers Health, Inc. (HIMS) reachead $11.88 at the closing of the latest trading day, reflecting a -0.17% change compared to its last close.

Zacks Investment Ideas feature highlights: Hims & Hers Health, Coinbase Global

Hims & Hers Health, Coinbase Global have been highlighted in this Investment Ideas article.

Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $12.34, moving -0.56% from the previous trading session.

Ethan Feller headshot

Investing in Growth: 2 Top-Ranked Stocks with Huge Potential

Strong sales growth is a beacon for investors seeking promising companies

Hims & Hers Health, Inc. (HIMS) Rises But Trails Market: What Investors Should Know

In the closing of the recent trading day, Hims & Hers Health, Inc. (HIMS) stood at $14.60, denoting a +0.34% change from the preceding trading day.

What Makes Hims & Hers Health, Inc. (HIMS) a Strong Momentum Stock: Buy Now?

Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.

Why Hims & Hers Health, Inc. (HIMS) Might be Well Poised for a Surge

Hims & Hers Health, Inc. (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Lilly (LLY) Starts Website to Help Access Tirzepatide Drugs

Eli Lilly's (LLY) digital pharmacy is expected to provide patients easy access to its FDA-approved tirzepatide medicines, Mounjaro and Zepbound.

Hims & Hers Health, Inc. (HIMS) Moves 8.3% Higher: Will This Strength Last?

Hims & Hers Health, Inc. (HIMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts Predict a 70.23% Upside in Hims & Hers Health, Inc. (HIMS): Here's What You Should Know

The consensus price target hints at a 70.2% upside potential for Hims & Hers Health, Inc. (HIMS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Hims & Hers Health, Inc. (HIMS) Reports Q3 Loss, Tops Revenue Estimates

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -33.33% and 3.03%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Reports Q2 Loss, Tops Revenue Estimates

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 50% and 1.61%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Privia Health (PRVA) Q2 Earnings and Revenues Surpass Estimates

Privia Health (PRVA) delivered earnings and revenue surprises of 20% and 5.36%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Inspire Medical Systems (INSP) Reports Q2 Loss, Tops Revenue Estimates

Inspire (INSP) delivered earnings and revenue surprises of 19.61% and 9.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Talkspace, Inc. (TALK) Reports Q2 Loss, Tops Revenue Estimates

Talkspace, Inc. (TALK) delivered earnings and revenue surprises of 50% and 7.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Benjamin Rains headshot

How to Find the Best Cheap Stocks Under $10 to Buy in July

Today we dive into a pocket of the stock market that many investors like to own as part of diversified portfolios: cheap stocks trading for $10 a share or less. Along with the cheap price tag, the stocks we explore today boast high Zacks Ranks given their improving earnings outlooks.

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

Smart Beta ETF report for FYC

Is First Trust Small Cap Core AlphaDEX ETF (FYX) a Strong ETF Right Now?

Smart Beta ETF report for FYX

Is Hims & Hers Health (HIMS) Stock Outpacing Its Medical Peers This Year?

Here is how Hims & Hers Health, Inc. (HIMS) and Apollo Medical Holdings, Inc. (AMEH) have performed compared to their sector so far this year.

Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates

Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 16.67% and 6.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is First Trust Small Cap Growth AlphaDEX ETF (FYC) a Strong ETF Right Now?

Smart Beta ETF report for FYC

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -15.79% and 4.22%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Hims & Hers Health, Inc. (HIMS) Surges 10.3%: Is This an Indication of Further Gains?

Hims & Hers Health, Inc. (HIMS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.